First United Bank Trust Lowers stake in Bristol-Myers Squibb Co (BMY)

Bristol-Myers Squibb Co (BMY) : First United Bank Trust reduced its stake in Bristol-Myers Squibb Co by 2.89% during the most recent quarter end. The investment management company now holds a total of 39,884 shares of Bristol-Myers Squibb Co which is valued at $2,714,106 after selling 1,187 shares in Bristol-Myers Squibb Co , the firm said in a disclosure report filed with the SEC on Apr 11, 2016.Bristol-Myers Squibb Co makes up approximately 2.47% of First United Bank Trust’s portfolio.

Bristol-Myers Squibb Co opened for trading at $67.94 and hit $68.3 on the upside on Friday, eventually ending the session at $68.05, with a gain of 0.27% or 0.18 points. The heightened volatility saw the trading volume jump to 32,47,446 shares. Company has a market cap of $113,607 M.

Other Hedge Funds, Including , First Premier Bank boosted its stake in BMY in the latest quarter, The investment management firm added 160 additional shares and now holds a total of 5,688 shares of Bristol-Myers Squibb Co which is valued at $375,294. Bristol-Myers Squibb Co makes up approx 0.30% of First Premier Bank’s portfolio.Nadler Financial Group boosted its stake in BMY in the latest quarter, The investment management firm added 21 additional shares and now holds a total of 7,570 shares of Bristol-Myers Squibb Co which is valued at $499,469. Bristol-Myers Squibb Co makes up approx 0.22% of Nadler Financial Group’s portfolio.First American Trust Fsb boosted its stake in BMY in the latest quarter, The investment management firm added 21,797 additional shares and now holds a total of 96,005 shares of Bristol-Myers Squibb Co which is valued at $6,334,410. Bristol-Myers Squibb Co makes up approx 2.24% of First American Trust Fsb’s portfolio.

On the company’s financial health, Bristol-Myers Squibb Co reported $0.38 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $0.28. The company had revenue of $4287.00 million for the quarter, compared to analysts expectations of $4154.19 million. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.46 EPS.

Many Wall Street Analysts have commented on Bristol-Myers Squibb Co. Societe Generale Initiated Bristol-Myers Squibb Co on Apr 6, 2016 to “Sell”, Price Target of the shares are set at $48.Bristol-Myers Squibb Co was Upgraded by Berenberg to ” Buy” on Jan 22, 2016.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery development licensing manufacturing marketing distribution and sale of biopharmaceutical products across the world. The Company’s products are sold to wholesalers retail pharmacies hospitals government entities and the medical profession. The Company manufactures its products in the United States Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers such as doctors nurse practitioners physician assistants pharmacists technologists hospitals Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print radio television and digital advertising and promotion. In addition the Company holds rights to F001287 which is a preclinical small-molecule IDO1-inhibitor.

Leave a Reply

Bristol-Myers Squibb Co - Is it time to Sell?

Top Brokerage Firms are advising their investors on Bristol-Myers Squibb Co. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.